30 July 2013 | News | By BioSpectrum Bureau
The partnership will create a one-stop source for a comprehensive line of vision care diagnostic devices and therapeutic lasers
Singapore: Lumenis, the world's largest medical laser company for ophthalmic, aesthetic, and surgical applications, and Visionix, a worldwide leader in wavefront technology for visual acuity and lens mapping, entered in a strategic agreement for Lumenis to distribute the Visionix ophthalmic and optometric diagnostics product line in China.
The partnership will create a one-stop source for a comprehensive line of vision care diagnostic devices and therapeutic lasers, allowing ophthalmologists and optometrists to offer their patients cost-effective and clinically-proven vision solutions. This newly announced partnership with Visionix will allow Lumenis to build on its robust presence in the Asia Pacific region and further expands its product offering.
Mr Kfir Azoulay, VP and GM, global ophthalmology business, Lumenis, said that, "In the ophthalmology world, Lumenis has built an unparalleled track record for delivering technological breakthroughs and our products are used as the industry gold-standard for glaucoma and retina treatments. Visionix also has a reputation as a technology leader, so this distribution agreement lays the foundation for broader future collaboration. We are thrilled to now offer our customers in the high-growth Chinese market a continuum of solutions, ranging from diagnostic to therapeutic vision care products."
Dr Marc Abitbol, president and CEO, Visionix, said that, "We are very excited to embark on this strategic alliance with Lumenis as our two companies' product lines complement each other perfectly. Lumenis is renowned in the ophthalmic industry for its performance, customer support and strong brand name. This business cooperation will allow the Visionix team to continue developing outstanding ophthalmic and optometry diagnostic products that exceed customer expectations, while meaningfully increasing our global market reach into emerging markets."